Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M

Personalis, Inc.

2024-Q2 EPS reported -$0.50 revenue$42,105,000

Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).
Net loss $12.8M, improved from $24.0M loss in Q2 2023; cash $87.0M.
FY 2024 revenue guidance raised to $79-81M from $76-78M; non-GAAP net loss ~$75M.
Cross-license agreement with Myriad Genetics; settled IP lawsuit with Foresight Diagnostics.
Delivered 561 molecular tests in Q2, up 66% QoQ; launched NeXT Personal Dx with Tempus AI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.